Switching from a vitamin K antagonist to a NOAC

被引：2
|
作者：
Senoo, Keitaro [1 ]
Lip, Gregory Y. H. [1 ,2 ]
机构：
[1] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
[2] Aalborg Univ, Aalborg Thrombosis Res Unit, Dept Clin Med, Aalborg, Denmark
来源：
LANCET HAEMATOLOGY | 2015年 / 2卷 / 04期
关键词：
ATRIAL-FIBRILLATION; DABIGATRAN; ANTICOAGULATION; PREVENTION; WARFARIN; STROKE; EVENTS;
D O I：
10.1016/S2352-3026(15)00041-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E132 / E133
页数：2
相关论文
共 50 条
  • [21] Non-vitamin K antagonist oral anticoagulant discontinuation in non-valvular atrial fibrillation patients (ASPECT-NOAC)
    Asilturk, E.
    Tulmac, M.
    Badak, O.
    Onal, T.
    Aras, D.
    Aciksari, G.
    Alper, A. T.
    Celik, A.
    Katicibasi, T.
    Ozdogan, O.
    EUROPEAN HEART JOURNAL, 2021, 42 : 576 - 576
  • [22] Drug Adherence in Patients With Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey: NOAC-TR
    Emren, Sadik Volkan
    Senoz, Oktay
    Bilgin, Murat
    Beton, Osman
    Aslan, Abdullah
    Taskin, Ugur
    Aciksari, Gonul
    Asarcikli, Lale Dinc
    Cakir, Hakan
    Bekar, Lutfu
    Bolat, Ismail
    Yayla, Cagri
    Celebi, Baris
    Dalgic, Onur
    Celik, Oguzhan
    Safak, Ozgen
    Akyel, Serdar
    Gungor, Hasan
    Duzel, Baris
    Zoghi, Mehdi
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2018, 24 (03) : 525 - 531
  • [23] Tecarfarin: A Novel Vitamin K Antagonist
    Hobl, Eva-Luise
    Jilma, Bernd
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (11) : 2009 - 2011
  • [24] Mortality of Intracerebral hemorrhage caused by Non-vitamin K Antagonist Oral Anticoagulant(NOAC) is lower than warfarin induced hemorrhage (WIH)
    Han, M. K.
    Woo, H. G.
    CEREBROVASCULAR DISEASES, 2018, 45 : 60 - 60
  • [25] Vitamin K Antagonist Use and Fracture
    Lau, Wallis C. Y.
    Man, Kenneth K. C.
    Wong, Ian C. K.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (01) : 396 - 397
  • [26] Vitamin K Antagonist Use and Fracture
    Wallis C. Y. Lau
    Kenneth K. C. Man
    Ian C. K. Wong
    Journal of General Internal Medicine, 2020, 35 : 396 - 397
  • [27] Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation
    Pallisgaard, Jannik Langtved
    Gislason, Gunnar Hilmar
    Torp-Pedersen, Christian
    Lee, Christina Ji-Young
    Sindet-Pedersen, Caroline
    Staerk, Laila
    Olesen, Jonas Bjerring
    Lindhardt, Tommi Bo
    PLOS ONE, 2016, 11 (08):
  • [28] Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN
    Miert, Jasper H. A. van
    Kooistra, Hilde A. M.
    Veeger, Nic J. G. M.
    Westerterp, Annelies
    Piersma-Wichers, Margriet
    Meijer, Karina
    THROMBOSIS RESEARCH, 2020, 190 : 69 - 75
  • [29] Assessment of treatment patterns and patient awareness in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants (ASPECT-NOAC)
    Badak, Ozer
    Demir, Ali Riza
    Onal, Tugay
    Akgun, Taylan
    Yontar, Osman Can
    Satiroglu, Omer
    Duman, Hakan
    Okuyan, Ertugrul
    Melek, Mehmet
    Dural, Ibrahim Etem
    IJC HEART & VASCULATURE, 2022, 39
  • [30] Vitamin-K antagonist toxicity from empagliflozin dispensing error
    Schmitz, Zachary P.
    Su, Mark K.
    Hoffman, Robert S.
    CLINICAL TOXICOLOGY, 2023, 61 : 103 - 104
12345